MJT & Associates Financial Advisory’s Biogen BIIB Stock Holding History

MJT & Associates Financial Advisory’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.24K	Buy	+15	New	+$2.87K	﹤0.01%	335

Other funds holding BIIB

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

ADEF

Adams Diversified Equity Fund Baltimore, Maryland $3.27B AUM 45.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

MJT & Associates Financial Advisory's BIIB Position: Q2 2026 in Review

MJT & Associates Financial Advisory opened a new position in Biogen (BIIB) in Q2 2026: 15 shares worth $3.24K. The stake represents ﹤0.01% of the portfolio and ranks #335 among its holdings.

269 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

MJT & Associates Financial Advisory held 15 shares of Biogen worth $3.24K as of Q2 2026.
Biogen was a new MJT & Associates Financial Advisory position in Q2 2026.
Biogen made up ﹤0.01% of MJT & Associates Financial Advisory's portfolio in Q2 2026, its #335 holding.
269 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on MJT & Associates Financial Advisory's 13F filing for Q2 2026, filed 6 Jul 2026.